STOCK TITAN

ProMIS Neurosciences Inc. - PMN STOCK NEWS

Welcome to our dedicated news page for ProMIS Neurosciences (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on ProMIS Neurosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ProMIS Neurosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ProMIS Neurosciences's position in the market.

Rhea-AI Summary
ProMIS Neurosciences Inc. (Nasdaq: PMN) announced that CEO Neil Warma will present at the 2024 BIO CEO & Investor Conference in New York. The company will also conduct one-on-one meetings during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.14%
Tags
conferences
-
Rhea-AI Summary
ProMIS Neurosciences Inc. (Nasdaq: PMN) has announced the selection of a lead vaccine candidate, PMN400, targeting synucleinopathies including Multiple System Atrophy, Parkinson’s disease, and Dementia with Lewy bodies. The company is focused on developing therapeutics for neurodegenerative diseases by targeting toxic misfolded proteins. This announcement marks a significant advancement in the company's efforts to address these debilitating conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.24%
Tags
none
-
Rhea-AI Summary
ProMIS Neurosciences Inc. (Nasdaq: PMN) issues a letter to shareholders, highlighting the progress of their lead clinical drug candidate, PMN310, in the treatment of Alzheimer’s disease. The company's unique scientific platform leverages AI to identify novel epitopes on toxic misfolded proteins, leading to the development of antibodies with high specificity and affinity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
none
Rhea-AI Summary
ProMIS Neurosciences Inc. (Nasdaq: PMN) appoints Neil Warma as Interim Chief Executive Officer, following the departure of Gail Farfel, Ph.D. The company remains focused on advancing the ongoing clinical program for PMN310 in Alzheimer’s disease and forging strategic partnerships to accelerate groundbreaking drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags
management
-
Rhea-AI Summary
ProMIS Neurosciences Inc. (Nasdaq: PMN) announced the publication of study results in Acta Neuropathologica Communications supporting the targeting of RACK1 as a potential therapeutic approach for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD). The study identifies RACK1 as a novel misfolded protein target for ALS and FTLD, providing another target for the company's pipeline as they advance clinical development of their lead product, PMN310, for Alzheimer’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
-
Rhea-AI Summary
ProMIS Neurosciences Inc. (Nasdaq: PMN) has initiated a first-in-human Phase 1a clinical trial of PMN310, a novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ), which are believed to be a major driver of Alzheimer’s disease (AD). The Company aims to develop better therapeutics for neurodegenerative diseases, leveraging recent results from a third-party clinical study to potentially differentiate PMN310 from other available treatments. The Phase 1a study will enroll up to five cohorts of eight adult healthy volunteers, with initial safety and pharmacokinetic (PK) data expected to be shared in the first half of 2024. Subsequent Phase 1b study in patients with Mild Cognitive Impairment (MCI) due to AD and patients with mild AD will be facilitated by the Phase 1a results, providing important insights into the safety profile of PMN310.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
clinical trial
Rhea-AI Summary
ProMIS Neurosciences Inc. (Nasdaq: PMN) raised $20.4 million in PIPE gross proceeds to support the development of PMN310 and novel antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases. The company also provided an update on their clinical and corporate initiatives, including the dosing of the first subjects in a Phase 1a clinical trial of PMN310 for Alzheimer’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
earnings
-
Rhea-AI Summary
ProMIS Neurosciences closes PIPE financing, raising approximately $20.4 million for clinical development and general expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary
ProMIS Neurosciences to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
conferences
Rhea-AI Summary
ProMIS Neurosciences announces a $20.4 million fundraise through a private investment in public equity (PIPE) financing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.75%
Tags
none
ProMIS Neurosciences Inc.

Nasdaq:PMN

PMN Rankings

PMN Stock Data

39.09M
10.92M
23.23%
17.78%
0.15%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Canada
Toronto

About PMN

promis™ neurosciences, inc. (tse: pmn, https://ca.finance.yahoo.com/q/bc?s=pmn.to), is a development stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular alzheimer’s disease (ad) and amyotrophic lateral sclerosis (als). the company’s scientific foundation centers on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. several neurodegenerative diseases exhibit protein misfolding, such as ad, als, and parkinson’s disease (pd). recent published evidence indicates that for a given misfolded protein there exist multiple prion-like strains, each strain representing a specific target against which specific therapeutics can be developed. the company is focused on the discovery and development of precision therapeutics and companion diagnostics to combat the several strains of beta-amyloid (aβ) and tau i